Actively Recruiting
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Led by Context Therapeutics Inc. · Updated on 2026-04-13
80
Participants Needed
13
Research Sites
198 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody, in participants with platinum-refractory/resistant ovarian cancer (PRROC) and other advanced CLDN6-positive solid tumors (i.e., testicular and endometrial).
CONDITIONS
Official Title
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants with CLDN6 positive platinum resistant/refractory ovarian, advanced testicular or advanced endometrial cancer.
- Participants with measurable disease per RECIST 1.1.
- ECOG 0, 1, or 2 and life expectancy of 2 12 weeks.
- Participants with adequate organ function.
You will not qualify if you...
- Evidence of central nervous system metastases, leptomeningeal disease or spinal cord compression.
- Uncontrolled significant active infection or any medical or other condition that in opinion of the Investigator would preclude the participant's participation in the study.
- Concurrent participation in another investigational clinical trial.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 13 locations
1
University of Arkansas Winthrop P. Rockefeller Cancer Institute
Little Rock, Arkansas, United States, 72205
Actively Recruiting
2
Precision NextGen Oncology & Research Center
Beverly Hills, California, United States, 90212
Withdrawn
3
SCRI at Denver Health
Denver, Colorado, United States, 80218
Actively Recruiting
4
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
5
John Theurer Cancer Center
Hackensack, New Jersey, United States, 07601
Terminated
6
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10021
Actively Recruiting
7
Duke Cancer Institute
Durham, North Carolina, United States, 27710
Actively Recruiting
8
Gabrail Cancer Center
Canton, Ohio, United States, 44718
Withdrawn
9
Providence Cancer Institute of Oregon
Portland, Oregon, United States, 97213
Actively Recruiting
10
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
Withdrawn
11
Women & Infants Hospital of Rhode Island
Providence, Rhode Island, United States, 02905
Actively Recruiting
12
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States, 37232
Actively Recruiting
13
SCRI at Mary Crowley
Dallas, Texas, United States, 75230
Actively Recruiting
Research Team
M
MaryBeth LeRose
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here